Merck wins U.S. FDA approval for expanded use of antibiotic


FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

(Reuters) – The U.S. Food and Drug Administration on Monday approved expanded use of Merck & Co Inc’s antibiotic to treat hospital-acquired pneumonia in patients 18 years and older.

The approval is based on late-stage trial results of the treatment, Zerbaxa, which showed that Merck’s drug was as effective as the antibiotic meropenem.

Hospital-acquired pneumonia occurs in patients at least two-three days after being admitted or in those who are on mechanical breathing machines and have life-threatening lung infections with high mortality rates.

Reporting by Saumya Sibi Joseph and Manojna Maddipatla in Bengaluru; Editing by Maju Samuel

Our Standards:The Thomson Reuters Trust Principles.


Please enter your comment!
Please enter your name here